Stockreport

Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights

Arcellx, Inc.  (ACLX) 
PDF -- Recently released ASH abstracts for the company’s Phase 1 and iMMagine-1 studies investigating anito-cel in relapsed or refractory multiple myeloma patients continue [Read more]